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Abstract
The RTS,S/AS candidate malaria vaccine has demonstrated efficacy against a variety of endpoints in
Phase IIa and Phase IIb trials over more than a decade. A multi-country phase III trial of RTS,S/AS01
is now underway with submission as early as 2012, if vaccine safety and efficacy are confirmed. The
immunologic basis for how the vaccine protects against both infection and disease remains
uncertain. It is, therefore, timely to review the information currently available about the vaccine
with regard to how it impacts the human-Plasmodium falciparum host-pathogen relationship. In this
article, what is known about mechanisms involved in partial protection against malaria induced by
RTS,S is reviewed.
Background
Against a background of variably shifting malaria disease
burden and a scale-up in the implementation of artemisi-
nin-based combination therapy, long-lasting insecticidal
nets and in some settings, indoor residual spraying, Plas-
modium falciparum malaria remains the commonest cause
of under-five mortality in several countries[1]. After four
decades of malaria vaccine development, a pivotal phase
III trial is underway of a vaccine which may be suitable for
licensure and assessment for implementation in malaria-
endemic countries. This vaccine, RTS,S/AS, is based on the
hepatitis B surface antigen virus-like particle (VLP) plat-
form, genetically-engineered to include the carboxy termi-
nus (amino acids 207-395) of the P. falciparum
circumsporozoite (CS) antigen[2]. The hybrid malaria-
hepatitis B VLP is lyophilized and undergoes point-of-use
reconstitution with GlaxoSmithKline's AS01 adjuvant, a
mixture of liposomes, MPL and QS21[3]. RTS,S has dem-
onstrated clinical efficacy against both infection and clin-
ical malaria in several well-designed phase II field efficacy
trials in both adults and children, replicated at several trial
sites [4-7]. The considerations of generalizability of effi-
cacy in different geographic and transmission settings,
duration of efficacy and confirmation of efficacy against
severe malaria are all to be addressed in the phase III
trial[8]. A large database will also be available to provide
information on safety of the novel adjuvant AS01E.
Here, the available evidence is re-assessed from clinical tri-
als of the relationships between parasite biology, vaccine-
induced immune responses and efficacy for circumsporo-
zoite (CS) -based malaria vaccines.
Localization and functions of CS protein
What is known about the role of the CS protein in malaria
parasite biology and pathogenesis has been reviewed pre-
viously[9,10]. Initially identified as a Plasmodium berghei
ortholog antigen Pb44, the CS protein[11] was shown to
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be the target of protective antibodies to the sporozoite sur-
face in murine models over 25 years ago [12-14]. CS cov-
ers the entire surface of sporozoites[15], the form of the
malaria parasite inoculated into humans by female
anopheline mosquitoes, and is found on the plasma
membrane of liver-stage parasites, which develop after
sporozoite invasion of hepatocytes. CS has been detected
in the cytoplasm of infected hepatocytes and a recent
report indicated that CS plays a role in suppression of
liver-stage inflammatory responses in a P. berghei
model[16]. CS is secreted at the apex of sporozoites,
becomes an integral component of the plasma membrane
and is continuously released in large amounts at the distal
tip of the sporozoite during gliding motility[17,18].
Many observations point to a region of CS as one of the
key ligands for adherence to the heparan suphate prote-
oglycan components of the liver sinusoidal lining prior to
hepatocyte invasion[10]. Incubation of live sporozoites in
vitro with anti-CS antibodies induces a characteristic mor-
phological change in sporozoite appearance with cessa-
tion of motility and shedding of sporozoite surface
material. This change, dubbed the circumsporozoite pre-
cipitin reaction, was first reported with antibodies raised
by irradiated sporozoite immunization[19,20], and later
with antibodies raised through immunization with only
the conserved Asparagine-Alanine-Asparagine-Proline
(NANP) amino acid repeat sequence which forms the
immunodominant B-cell epitope from P. falciparum CS
antigen[15]. This sequence is species-specific, but highly
conserved for isolates from each species.
Clinical trial immunogenicity and efficacy
CS-based malaria vaccine development has progressed
through iterations using clinical challenge model efficacy
as a means of guiding improvements to vaccine design
[21-27]. The story of this iterative development in the late
1980s and 1990s, leading up to selection of RTS,S for field
trials, is well documented including several review publi-
cations. Interested readers are referred to these
reviews[2,28-30]. RTS,S/AS01 induces very high IgG con-
centrations in vaccinated humans to the NANP CS repeat.
In addition, this vaccine induces moderate to high CD4+
Th1 responses against flanking region peptides[31].
Immune correlates of protection are known to exist for
some vaccines and these permit licensure of new forms of
these vaccines and extension of vaccine indications to new
populations based on immunogenicity endpoints with-
out a requirement to demonstrate vaccine efficacy
(reviewed in [32]). In the case of malaria vaccines, there is
no known link between immunogenicity and protection
and, therefore, no accepted in vitro correlates of protec-
tion[33]. Moreover, the parasite is complex with multiple
antigens that are potential targets of naturally acquired
immunity. The CS antigen is not thought to be an impor-
tant target of naturally acquired immunity by individuals
repeatedly exposed to malaria-infected mosquitoes.
Analysis of association between immune responses and
clinical efficacy have limited utility where the sample size
is small, unless the relationship is simple and generaliza-
ble amongst vaccinees. Nevertheless, the available experi-
mental human sporozoite challenge trial data for RTS,S
with both AS01 and AS02 adjuvants is consistent with an
important role of anti-NANP IgG in protection from infec-
tion. Each of the challenge studies were necessarily small,
with generally too few protected individuals to usefully
explore this relationship, in more than an indicative man-
ner[25]. It should be noted that even life-long exposure to
large numbers of malaria-infected mosquitoes rarely
induces an anti-CS antibody response in excess of 10 μg/
mL[34,35] using a qualified ELISA where the capture anti-
gen consists of NANP repeats, and in infants and children
living under these conditions, the values rarely exceed 0.5
μg/mL[36].
It has not proved possible to derive a protective threshold
for CS repeat IgG concentration, although, should a
threshold exist, it probably lies above 20 μg/mL for most
individuals: in 10 challenge trials of CS vaccines con-
ducted between 1986 and 2001, only five of 108 volun-
teers with CS repeat IgG levels below 20 μg/ml were
protected, whereas 14 of 27 volunteers with IgG levels
above 20 μg/ml were protected[37]. A phase IIa trial of
RTS,S/AS02 in 41 vaccinees reported a statistically signifi-
cant increase in the seroconversion rate above this 20 μg/
ml value for protected vaccinees compared to unprotected
volunteers[37]. However, in the same trial there was no
trend for protection with increasing IgG levels and
receiver operator characteristic analyses did not identify a
cut-off level for protection. In an analysis of 19 RTS,S/
AS02 vaccinees, in a later phase IIa trial, those protected
had higher CS repeat IgG levels than those unpro-
tected[38]. None of the vaccinees with an IgG level below
20  μg/ml were protected; some vaccinees with levels
above 20 μg/ml were not protected. In a further phase IIa
trial of RTS,S/AS02 with 40 vaccinated volunteers, an
analysis was performed dividing the vaccinees into three
groups: those completely protected from infection, those
with a delay in time to first detection of parasitaemia by
microscopy, indicating partial protection, and those not
protected[39]. In this analysis, the protected group (n =
16) had a geometric mean antibody concentration of
113.7 μg/ml. The equivalent figures for the partially pro-
tected (n = 14) and unprotected (n = 8) groups were 67.5
μg/ml and 29.6 μg/ml. These differences were statistically
significant[19], and the absolute peak IgG concentrations
induced in immunized protected volunteers are clearly
very high. The largest Phase IIa trial of RTS,S confirmedMalaria Journal 2009, 8:312 http://www.malariajournal.com/content/8/1/312
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the strong association between anti-CS IgG titre and pro-
tection against infection and demonstrated an independ-
ent, albeit weaker, association between CS- specific CD4+
T cell responses and protection[31]. This trial has not
reported on potential threshold levels to date.
The first Phase IIb field efficacy trial, which involved 306
Gambian adults, reported 34% efficacy against the inci-
dence rate of first blood stage infections over a 15-week
period. In this study a linear relationship was found
between IgG concentration post dose 3 and protection
from blood stage infection, such that the odds ratio for a
ten-fold increase in IgG concentration was 0.21 (p =
0.023). After correction for age and pre-vaccination titre
the odds ratio was 0.27 (p = 0.07). There is some evidence
of naturally acquired immunity to infection as detected by
microscopy occurring in adolescence and adulthood. For
example, in two adult vaccine efficacy trials with primary
infection endpoints, the incidence of infection decreased
with increasing age in the 18-45 year age range[4,40] and
a decrease in parasite prevalence over this age range is well
documented in several studies from Kilifi, Kenya[41].
Given the very substantially greater data on naturally
acquired immunity targeting the blood stages of the para-
site compared to the pre-erythrocytic stages, it may be that
this naturally acquired immunity to infection is in fact a
gradual acquisition of the ability of anti-blood stage
immunity to suppress blood stage infection to sub-micro-
scopic parasite densities rather than sterilising pre-eryth-
rocytic immunity. This muddies the water to some extent
with regard to the question of whether vaccine or natu-
rally acquired responses account for protection from
infection in studies in older children and adults. Never-
theless, the best chance of detecting relationships between
immune responses and protection for pre-erythrocytic
vaccines is in field trials in endemic populations with sim-
ilarly low pre-existing antibodies reflecting prior exposure
to malaria, primary infection endpoints and, where the
entomological inoculation rate is high, pre-treatment of
volunteers prior to the efficacy follow-up period. Here the
efficacy endpoint is as close as possible to a likely biolog-
ical target of the immune response.
Questions remained as to whether this relationship
between anti-CS IgG and protection against infection
would hold in younger children or infants. It also
remained to be seen whether a similar relationship might
have been seen between IgG concentration and morbidity
endpoints. This would introduce a further variable which
is difficult to assess because there may not be a direct rela-
tionship between infection and disease: not all infections
become clinically manifest, it may not be possible to link
a specific clinical case to a specific infectious event, and
some mild cases of clinical disease may not be detectable.
It is likely that all cases of severe morbidity episodes are
detected in field trials, but the still poorly understood het-
erogeneity in risk of malaria introduces major complexi-
ties in extrapolating from infection to morbidity at the
individual level. Thus, a lack of association between
immune responses and anti-morbidity efficacy would not
necessarily be surprising. Furthermore exposure may not
be uniform and this has been shown to make immunity
harder to detect[42].
The largest Phase IIb field efficacy trial of RTS,S/AS02 to
date reported data on 2,022 Mozambican children aged 1-
4. In a commendable attempt to address the issue of effi-
cacy against both infection and clinical disease, two sepa-
rate cohorts were utilised. In one cohort (cohort 1),
passive case detection only was performed, without pre-
treatment, in order to assess efficacy against clinical dis-
ease. In cohort 2, children were pre-treated and active
detection of infection was performed with regular cross-
sectional blood sampling. Clinical malaria efficacy over
18 months after dose 3 in cohort 1 was 35.3%. There was
an unexpectedly high rate of severe malaria disease
detected during the study, allowing an estimation of vac-
cine efficacy against severe malaria of 48.6%[5,6]. A recent
paper reports for the first time on the association between
anti-NANP IgG and infection efficacy in cohort 2 of this
same trial[43,44]. Again there is a statistically significant
association between IgG concentration and efficacy
against infection. A similar association was reported in an
infant RTS,S Mozambican study [45]. In contrast two pae-
diatric randomized controlled field trials have now
reported a lack of association between the anti-NANP IgG
concentration and protection against clinical disease;
cohort 1 of the Mozambican study in children aged 1-4
and a trial conducted in Kenya and Tanzania in children
aged 5-17 months[5,7].
What can be deduced from the consistent pattern of asso-
ciations seen for anti-NANP IgG and protection from
infection with RTS,S, and the lack of association with mor-
bidity to date? Efficacy against morbidity should be a nat-
ural extension of efficacy against infection in that by
reducing the incidence of new infections, reducing the
multiplicity of infection and a reduction in parasite den-
sity of breakthrough infections should logically be
expected to interact with the expression of clinical malaria
disease and the acquisition of naturally acquired immu-
nity. One hypothesis proposed here is that this naturally
acquired blood-stage immunity component which cannot
be directly measured confounds analyses seeking to meas-
ure an association of immune responses against the spo-
rozoite with morbidity endpoints which involve a
completely different stage of the parasite that does not
share protective epitopes with the CS protein.
It should be noted that little is known about the fine spe-
cificity or functional activity of anti-NANP IgG and their
role in protection. Where it has been analysed, IgG1 andMalaria Journal 2009, 8:312 http://www.malariajournal.com/content/8/1/312
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IgG2 account for "nearly all" of the total IgG concentra-
tion of anti-NANP antibodies[25], with IgG1 being "the
dominant subclass"[37]. Sporozoite-opsonizing activity
has been demonstrated in vitro, where monocytes have
been shown to internalize and kill live sporozoites
exposed to plasma from RTS,S-immunized protected vac-
cinees[46]. Further characterization of the associations
between functional activities of anti-NANP IgG and pro-
tection is highly desirable and may inform refinements
planned for future CS-based vaccine candidates.
Vaccines may protect either through complete protection
of a proportion of vaccinees or through partial protection
of all vaccinees (or a combination of the two)[47]. Certain
characteristics of clinical efficacy data may point to one or
the other mode of vaccine effect. The RTS,S challenge and
field trial data to date are consistent with at least partial
protection in most or all volunteers. It is possible that
complete protection also occurs in some volunteers. It has
been established that RTS,S/AS reduces the rate of new
blood stage infections[5], reduces the initial inoculum of
each blood stage infection[48] and reduces the multiplic-
ity of infection[49] in vaccinees. Taken together these may
also foster acquisition of naturally acquired immunity to
malaria, whilst reducing the malaria morbidity in vac-
cinees. This mode of action has been called a "leaky vac-
cine". If RTS,S is indeed a leaky pre-erythrocytic malaria
vaccine, this needs to be taken into account in interpreting
associations of immune responses and efficacy, as partial
protection from infection would be expected in most indi-
viduals. Recent advances in understanding of the skin
stage of malaria, help us envisage how such partial protec-
tion could occur. When a mosquito probes for a blood
meal, sporozoites are deposited intradermally and
migrate for up to two hours before entering skin microv-
asculature or entering lymphatics[50]. However, there is a
wide range of skin transit times before sporozoites enter
the vasculature[51], with some sporozoites perhaps enter-
ing directly into vessels during mosquito probing. Anti-
sporozoite antibodies have been shown to reduce the
numbers of sporozoites which enter skin blood vessels to
begin the journey to the liver[52].
What is the role of cell-mediated immune (CMI)
responses in protection afforded by RTS,S? The published
literature indicates that there is evidence that CMI has an
important role when added to the foundation of robust
IgG responses. CMI indicators were used as a down-selec-
tion criterion for adjuvant choice in the RTS,S pro-
gramme[2]. Both CS-specific γ-interferon secreting CD4+
T cell responses (as enumerated by ex vivo ELSISPOT) and
multifunctional CS-specific CD4+ T cells (defined as
expressing two or more of γ-interferon, TNF, IL-2 and
CD40 ligand using an intracellular cytokine staining
assay) were greater in protected than in unprotected vac-
cinees in a recent RTS,S clinical challenge trial[31]. Multi-
functional CD4+ T cell responses were reported not to be
correlated with anti-NANP IgG responses. There are major
limitations in what CMI studies are possible with blood
volumes obtainable in paediatric trials, although some
data on CMI responses to RTS,S is now available in Afri-
can children[53]. Most RTS,S studies performing CMI
studies have reported an absence of substantial CS-spe-
cific CD8+ T cell responses[31,54]. Weak CS-specific
CD8+ T cell responses were reported in 1 study with a
highly sensitive ELISPOT assay performed on cultured
cells[55].
CS-specific CMI and vaccine efficacy
RTS,S-induced CS-specific CD4+ T cell frequency, as enu-
merated by both ex vivo ELISPOT and intracellular
cytokine staining, is associated with protection against
infection[31]. However the available data indicates that
IgG plays a more important role in RTS,S-mediated pro-
tection than CMI. The potential contribution of CD8+ T
cells in killing of intracellular hepatocyte infection is
unquestioned. This evidence stems from adoptive trans-
fers and pre-clinical models of whole organism and subu-
nit vaccine immunity [56-58] with some indirect evidence
from clinical studies[59,60]. CD8 T cells are thought to be
the critical determinant of irradiated sporozoite immu-
nity, at least in mouse models where immune mecha-
nisms can be dissected in detail[58]. There is, therefore,
good reason to believe that induction of robust liver-stage
specific CD8+ T cell responses in addition to RTS,S-
induced IgG and CD4+ T cells, could add to currently
achieved levels of clinical protection. There is also evi-
dence for the important role of CD4+ Th1 responses from
both pre-clinical adoptive transfer experiments[61] and
field trials[62]. Furthermore protective CD8+ responses
may be CD4+ T cell dependent[58]. Thus further improv-
ing upon currently attained CD4+ T cell magnitude may
augment RTS,S-induced protection[63]. It is worth noting
that modest CD4+ T cell ex vivo γ-interferon responses
alone at an arithmetic mean of 129 spot forming cells/
million PBMCs induced by DNA/modified vaccinia virus
Ankara prime-boost delivery of P. falciparum CS were not
associated with efficacy in a sporozoite challenge trial in
the UK[64].
Conclusions
The available evidence about the protective mechanism of
RTS,S/AS strongly supports a critical role for IgG against
the CS repeat sequence in the protection seen against
infection, whether in multiple clinical challenge trials in
USA, adult or paediatric field trials in different age groups
and across the distinct transmission settings of The Gam-
bia, Kenya, Tanzania and Mozambique. Two conclusions
follow from this fact. Firstly, future attempts at improve-
ments of RTS,S-mediated protection should be rooted inMalaria Journal 2009, 8:312 http://www.malariajournal.com/content/8/1/312
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at least matching the potent IgG response. Secondly,
exploratory studies to shed some light on the fine specifi-
city and protective mechanism of the IgG response are a
high priority. These same data do not support identifica-
tion to date of an absolute correlate of protection in the
sense of a threshold level where complete protection is
conferred at the individual level against a defined end-
point, but this lack of an absolute correlate does not
change the above conclusions. The relationship between a
protective immune response and reduction in risk of a
defined malaria endpoint, be it infection or clinical dis-
ease, could perhaps be described graphically (see Figure
1). This type of representation of correlates of immunity
has been performed for some other diseases[32] and it
may be beneficial for this sort of analysis to be attempted
for RTS,S-induced immune responses and malaria effi-
cacy.
There is supportive evidence, although weaker than that
for the role of antibodies, that CS-specific CD4+ T cell
responses are independently associated with protection
against infection. A parsimonious interpretation is that
such CD4+ T cell responses and IgG are additive in their
protective effect for RTS,S. In some individuals a protec-
tive effect of moderate antibody concentrations may be
complemented by a strong T cell response and vice versa.
From this it follows that second generation vaccines that
are able to match the protective B cell response seen in
RTS,S vaccinees, but improve on the CMI aspect, would
have a good chance of inducing higher efficacy. A valid
hypothesis for vaccine approaches, which induce CMI
responses without antibody induction, is whether spectac-
ular CMI responses an order of magnitude higher than has
been seen to date with CS-based vaccines could protect in
the absence of antibodies. Though an interesting research
question, this is a higher risk approach than dual induc-
tion of potent IgG and CMI.
Given the recent demonstration of partial efficacy in
humans through prime-boost immunization with the
ME-TRAP construct in the UK, two approaches appear
highly worthy of attention from a technical perspective.
These are matching the potent IgG response induced by
RTS,S, and improving upon either the malaria-specific
CD8+ or the CD4+ T cell responses.
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